Abstract
BackgroundRenal cell carcinoma (RCC) is one of the most common malignancies worldwide. Noninvasive imaging techniques, such as magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET), have been involved in increasing evolution to detect RCC. This meta-analysis aims to compare to compare the performance of MRI, SPECT, and PET in the detection of RCC in humans, and to provide evidence for decision-making in terms of further research and clinical settings.MethodsElectronic databases including PubMed, Web of Science, Embase, and Cochrane Library were systemically searched. The keywords such as “magnetic resonance imaging”, “MRI”, “single-photon emission computed tomography”, “SPECT”, “positron emission tomography”, “PET”, “renal cell carcinoma” were used for the search. Studies concerning MRI, SPECT, and PET for the detection of RCC were included. Pooled sensitivity, specificity, and the area under the summary receiver operating characteristic (SROC) curve (AUC), etc. were calculated.ResultsA total of 44 articles were finally detected for inclusion in this study. The pooled sensitivities of MRI, 18F-FDG PET and 18F-FDG PET/CT were 0.80, 0.83, and 0.89, respectively. Their respective overall specificities were 0.90, 0.86, and 0.88. The pooled sensitivity and specificity of MRI studies at 1.5 T were 0.86 and 0.94, respectively. With respect to prospective PET studies, the pooled sensitivity, specificity and AUC were 0.90, 0.93 and 0.97, respectively. In the detection of primary RCC, PET studies manifested a pooled sensitivity, specificity, and AUC of 0.77, 0.80, and 0.84, respectively. The pooled sensitivity, specificity, and AUC of PET/CT studies in detecting primary RCC were 0.80, 0.85, and 0.89.ConclusionOur study manifests that MRI and PET/CT present better diagnostic value for the detection of RCC in comparison with PET. MRI is superior in the diagnosis of primary RCC.
Highlights
Renal cancer is one of the most frequently diagnosed cancers worldwide, which ranks the 6th most frequently confirmed malignant tumor in men and the 8thYin et al BMC Cancer (2022) 22:163 diseases even after surgical resection [6, 7]
positron emission tomography (PET) plays an important role in the detection of recurrent or metastatic Renal cell carcinoma (RCC) [22, 23]
The following key terms were used for the database research: “magnetic resonance imaging”, “MRI”, “single-photon emission computed tomography”, “single photon emission computed tomography (SPECT)”, “positron emission tomography”, “PET”, “renal cell carcinoma”
Summary
Renal cancer is one of the most frequently diagnosed cancers worldwide, which ranks the 6th most frequently confirmed malignant tumor in men and the 8thYin et al BMC Cancer (2022) 22:163 diseases even after surgical resection [6, 7]. Single photon emission computed tomography-computed tomography (SPECT) imaging is used to differentiate RCC and detect metastases in renal cancer [15, 16]. Renal cell carcinoma (RCC) is one of the most common malignancies worldwide Noninvasive imaging techniques, such as magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET), have been involved in increasing evolution to detect RCC. This meta-analysis aims to compare to compare the performance of MRI, SPECT, and PET in the detection of RCC in humans, and to provide evidence for decision-making in terms of further research and clinical settings
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.